Cannabis Sativa Announces Q1 2021 Revenues
Cannabis Sativa, Inc. (OTCQB:CBDS) reported Q1 2021 revenues of $557,323, with its subsidiary PrestoDoctor contributing $482,350 and achieving a margin of 62%. This represents a 13% growth compared to Q1 2020. Management anticipates further growth driven by PrestoDoctor’s expansion into newly legalized states for medical marijuana and effective advertising campaigns in Oklahoma and Iowa. The company aims to enhance its presence in the cannabis market through vertical integration, including cultivating its unique cannabis strain and acquiring dispensaries.
- Q1 2021 revenues of $557,323, a 13% increase from Q1 2020.
- PrestoDoctor generated $482,350 in gross revenue with a 62% margin.
- Expansion plans into new states with legalized medical marijuana are in progress.
- High customer satisfaction with nearly 15,000 five-star reviews for PrestoDoctor.
- None.
MESQUITE, NV / ACCESSWIRE / May 18, 2021 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces Q1 2021 revenues of
About PrestoDoctor
PrestoDoctor is rated the #1 online medical marijuana doctor referral service by tens of thousands of medical cannabis patients who have received fully qualified medical marijuana recommendations. PrestoDoctor is the only service to offer patients a custom treatment plan after they have a confidential evaluation with a licensed, highly knowledgeable physician who is an expert in treatment methods, dosing levels, and cannabis products. Founded in 2015, PrestoDoctor services are available in legal medical marijuana states: California, Missouri, New York, Nevada, Oklahoma, Pennsylvania, Illinois and now Iowa. A HIPAA and HITECH compliant telemedicine company, PrestoDoctor is a member of the American Telemedicine Association (ATA), maintaining the highest customer satisfaction rating for any telemedicine service online with nearly 15,000 5-star reviews.
About Cannabis Sativa, Inc.:
Since 2017, Cannabis Sativa, Inc. ("CBDS") has focused on telehealth, and more recently is exploring opportunities for direct involvement in the cannabis industry through touch the plant operations. We currently control a patented hybrid/landrace "Ecuadorian Sativa" strain of cannabis, and are commencing a grow to determine if the "CTA" strain can yield products with medicinal properties that motivate and energize, rather than create lethargy and sleepiness, attractive to a diverse range of cannabis consumers. We are also interested in acquiring multiple dispensaries to provide an outlet for several cannabis brands that we own or have rights to use through licensing arrangements, including Wild Earth Naturals®, the "hi" and "White Rabbit" brands, and the Virgin Mary Jane Brand. After an initial foray into contract manufacturing of CBD infused products through our controlled subsidiary, GK Manufacturing and Packaging, Inc., the Company is now looking to redirect its manufacturing capabilities to products containing THC. Our long-term intent is to become a vertically integrated grower, processor, manufacturer and distributor of cannabis products where we can achieve better control over the supply chain and the quality of biomass we use in our products. Our existing telehealth operations provide a market access point that may be advantageous as the cannabis market matures and inter-company competition for customers continues unabated. We are excited about the opportunities and look forward to the challenges ahead.
Forward-Looking Statements:
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact Information:
(702) 762-3123
https://www.cannabissativa.com
SOURCE: Cannabis Sativa, Inc.
View source version on accesswire.com:
https://www.accesswire.com/647876/Cannabis-Sativa-Announces-Q1-2021-Revenues
FAQ
What were the Q1 2021 revenues for Cannabis Sativa, Inc. (CBDS)?
How much revenue did PrestoDoctor generate in Q1 2021?
What is the revenue growth percentage for Cannabis Sativa in Q1 2021 compared to Q1 2020?
What margin did PrestoDoctor achieve in Q1 2021?
What states is PrestoDoctor planning to expand into after medical marijuana legalization?
